These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
917 related items for PubMed ID: 18635341
1. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Lin DF, Zhang YY, Wu JF, Wang F, Zheng JC, Miao JZ, Zheng LY, Sheng RY, Zhou X, Shen HH, Ijzerman MM, Croos-Dabrera RV, Sheng W. Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341 [Abstract] [Full Text] [Related]
4. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, Taylor L, Hayman S, Shaw S, Kibbler C, Shulman R, Singer M, Wilson AP. J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840 [Abstract] [Full Text] [Related]
6. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, Krause D, Satilovs I, Endzinas Z, Breaux J, O'Riordan W. Clin Infect Dis; 2005 Nov 15; 41(10):1407-15. PubMed ID: 16231250 [Abstract] [Full Text] [Related]
12. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Bounthavong M, Hsu DI. Curr Med Res Opin; 2010 Feb 15; 26(2):407-21. PubMed ID: 20001574 [Abstract] [Full Text] [Related]